ZA200810113B - Method for the treatment and prevention of ocular disorders - Google Patents

Method for the treatment and prevention of ocular disorders

Info

Publication number
ZA200810113B
ZA200810113B ZA2008/10113A ZA200810113A ZA200810113B ZA 200810113 B ZA200810113 B ZA 200810113B ZA 2008/10113 A ZA2008/10113 A ZA 2008/10113A ZA 200810113 A ZA200810113 A ZA 200810113A ZA 200810113 B ZA200810113 B ZA 200810113B
Authority
ZA
South Africa
Prior art keywords
treatment
prevention
ocular disorders
methods
ocular
Prior art date
Application number
ZA2008/10113A
Other languages
English (en)
Inventor
David Renwick Houck
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of ZA200810113B publication Critical patent/ZA200810113B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
  • Laser Surgery Devices (AREA)
ZA2008/10113A 2006-05-19 2008-11-27 Method for the treatment and prevention of ocular disorders ZA200810113B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80220806P 2006-05-19 2006-05-19
PCT/US2007/011919 WO2007136759A2 (en) 2006-05-19 2007-05-18 Method for the treatment and prevention of ocular disorders

Publications (1)

Publication Number Publication Date
ZA200810113B true ZA200810113B (en) 2010-02-24

Family

ID=37814449

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2008/10113A ZA200810113B (en) 2006-05-19 2008-11-27 Method for the treatment and prevention of ocular disorders

Country Status (12)

Country Link
US (2) US8188052B2 (enExample)
EP (1) EP2023918B1 (enExample)
JP (1) JP5377293B2 (enExample)
CN (1) CN101511357B (enExample)
AT (1) ATE502633T1 (enExample)
AU (1) AU2007254148B2 (enExample)
CA (1) CA2652662C (enExample)
DE (1) DE602007013391D1 (enExample)
DK (1) DK2023918T3 (enExample)
ES (1) ES2361635T3 (enExample)
WO (1) WO2007136759A2 (enExample)
ZA (1) ZA200810113B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1802650T3 (pl) * 2004-10-01 2012-04-30 Scynexis Inc 3-Etero i 3-tioetero podstawione pochodne cyklosporyny do leczenia i zapobiegania zakażeniu wirusem zapalenia wątroby typu C
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7202209B2 (en) * 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7754685B2 (en) 2005-09-30 2010-07-13 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
JP5322647B2 (ja) * 2005-09-30 2013-10-23 スシネキス インク ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体
US8188052B2 (en) 2006-05-19 2012-05-29 Scynexis, Inc. Method for the treatment and prevention of ocular disorders
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
CA2724523A1 (en) 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
WO2010076329A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
US8685917B2 (en) * 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
CA2782898A1 (en) * 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
JP5805773B2 (ja) * 2010-10-12 2015-11-10 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンアナログ
CA2814192A1 (en) 2010-10-12 2012-04-19 Allergan, Inc. Cyclosporin analogs
WO2012123515A1 (en) * 2011-03-14 2012-09-20 Drug Delivery Solutions Limited An ophthalmic composition
US10429712B2 (en) 2012-04-20 2019-10-01 View, Inc. Angled bus bar
US9266927B2 (en) 2012-06-01 2016-02-23 Allergan, Inc. Cyclosporin A analogs
CN105324708B (zh) 2013-06-18 2020-02-14 唯景公司 非矩形形状上的电致变色设备
US20150005186A1 (en) * 2013-06-27 2015-01-01 Jing-Feng Huang Methods and devices for classifying and managing autoimmune and inflammatory conditions
MX364310B (es) 2013-11-05 2019-04-22 Gustavo A Garcia Sanchez Método para preparar una formulación inmunosupresora.
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
KR102084341B1 (ko) * 2015-12-14 2020-03-03 요우 핑 차오 짧은 합성 펩티드 및 그의 용도
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途
US20200366476A1 (en) * 2019-05-17 2020-11-19 Panasonic Avionics Corporation Transient key negotiation for passenger accessible peripherals
JP2022551161A (ja) * 2019-10-12 2022-12-07 ファーサイト メディカル テクノロジー （シャンハイ） カンパニー リミテッド ネフロトキシン誘発性腎障害の処置及び予防
CN111920940B (zh) * 2020-09-16 2022-04-05 易舟(上海)生物医药有限公司 一种眼用制剂及其制备方法和应用
EP4126905A4 (en) * 2020-03-26 2024-05-29 Farsight Medical Technology (Shanghai) Co., Ltd. CYCLOPHILIN INHIBITORS AND THEIR USES
WO2021209003A1 (en) * 2020-04-15 2021-10-21 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
US11564909B2 (en) * 2020-11-30 2023-01-31 Romeg Therapeutics Llc Methods and compositions for oral pilocarpine liquid
WO2024245384A1 (en) * 2023-06-02 2024-12-05 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclophilin inhibitors and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4649047A (en) * 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4814323A (en) 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4885276A (en) 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5294604A (en) 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
DE69124459T3 (de) 1990-11-02 2001-05-31 Novartis Ag, Basel Zyklosporine
WO1994022896A1 (fr) 1993-03-31 1994-10-13 Tokyo Tanabe Company Limited Ameliorant de la cholestase
WO1995003056A1 (en) 1993-07-19 1995-02-02 Tokyo Tanabe Company Limited Hepatitis c virus proliferation inhibitor
HUP9900405A3 (en) 1995-07-17 2001-04-28 Scynexis Inc Durham Cyclosporin derivatives with anti-hiv effect
JP3089350B2 (ja) 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2762843B1 (fr) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2772768B1 (fr) 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
CN1205220C (zh) 1998-06-12 2005-06-08 斯－凯穆公司 新颖的环孢菌素
FR2780061B1 (fr) 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
BR9911724A (pt) 1998-07-01 2001-03-20 Debiopharm Sa Ciclosporina que tem um perfil de atividade melhorado
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6521595B1 (en) 1999-11-19 2003-02-18 Lg Chemical, Ltd. Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
RU2223761C2 (ru) 1999-12-27 2004-02-20 Джапан Тобакко Инк. Соединения с конденсированным кольцом и их использование в качестве лекарственных средств
MY139078A (en) 2000-07-21 2009-08-28 Schering Corp Peptides as ns3-serine protease inhibitors of hepatitis c virus
US6987090B2 (en) 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR20040039622A (ko) 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
WO2005000308A2 (en) 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
CN1984670A (zh) 2004-07-13 2007-06-20 诺瓦提斯公司 治疗阿尔茨海默病的环孢菌素
BRPI0513370A (pt) 2004-07-14 2008-05-06 Novartis Ag uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
JP2008514701A (ja) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
PL1802650T3 (pl) * 2004-10-01 2012-04-30 Scynexis Inc 3-Etero i 3-tioetero podstawione pochodne cyklosporyny do leczenia i zapobiegania zakażeniu wirusem zapalenia wątroby typu C
SG139750A1 (en) 2004-10-01 2008-02-29 Debiopharm Sa Ch Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3- [etval]4-cyclosporin
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US20090214464A1 (en) 2004-12-23 2009-08-27 Beat Weidmann Compounds for flaviviridae treatment
KR20070087624A (ko) 2004-12-23 2007-08-28 노파르티스 아게 Ｈｃｖ 치료용 조성물
US7754685B2 (en) 2005-09-30 2010-07-13 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
JP5322647B2 (ja) 2005-09-30 2013-10-23 スシネキス インク ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体
US8188052B2 (en) 2006-05-19 2012-05-29 Scynexis, Inc. Method for the treatment and prevention of ocular disorders
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
WO2008143996A1 (en) * 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
CA2724523A1 (en) 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
US20090306033A1 (en) 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
WO2010076329A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
CN102271688A (zh) 2009-01-07 2011-12-07 西尼克斯公司 用于治疗hcv的环孢菌素衍生物和核苷的组合
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
CA2782898A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides

Also Published As

Publication number Publication date
JP2009537550A (ja) 2009-10-29
CN101511357A (zh) 2009-08-19
CA2652662A1 (en) 2007-11-29
WO2007136759A2 (en) 2007-11-29
US20120270804A1 (en) 2012-10-25
DK2023918T3 (da) 2011-04-26
US20100062975A1 (en) 2010-03-11
AU2007254148B2 (en) 2013-02-07
US8551952B2 (en) 2013-10-08
WO2007136759A3 (en) 2009-04-16
EP2023918A2 (en) 2009-02-18
US8188052B2 (en) 2012-05-29
JP5377293B2 (ja) 2013-12-25
ATE502633T1 (de) 2011-04-15
EP2023918B1 (en) 2011-03-23
CN101511357B (zh) 2011-11-02
ES2361635T3 (es) 2011-06-20
DE602007013391D1 (de) 2011-05-05
CA2652662C (en) 2015-11-03
AU2007254148A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2010093849A3 (en) Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2007112014A3 (en) New therapeutic combinations for the treatment of depression
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
UA85707C2 (ru) Бензоксазины для лечения заболеваний дыхательных путей
PT2383271E (pt) Aminoquinolonas como inibidores de gsk-3
NZ600874A (en) Fluorinated derivatives of deferiprone
TW200738651A (en) Cyclohexyl sulfonamide derivatives
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2007005649A (es) Carboxiamidas de azaindol.
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
GB0416508D0 (en) Therapeutic agents
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
NZ597866A (en) Therapeutic lactams
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
WO2007147868A3 (en) Prevention of muscle atrophy
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
TW200634013A (en) Quinoline derivative, its use, production and pharmaceutical agents containing the derivative